Kornimate/medical-research-clean huggingface dataset:
study of the implication of omega-3 polyunsaturated fatty acids in retinopathy of prematurity in new-born infants

Conditions: Retinopathy of Prematurity

Summary: the development of the retinal vascular network is generally complete during the 3rd trimester of pregnancy but may continue during the first 15 days of life. this late maturation may cause problems in pre-term births and may result in immature vascularization of the retina, a condition called retinopathy of prematurity. among the different factors affecting the development of the retinal vasculature, the tissue level of omega-3 polyunsaturated fatty acids (pufa) appears to be a crucial element, as does the form of the pufa present in the tissues (nature of the phospholipids in their membranes). this project aims to show a possible association between levels of omega-3 pufa and the onset of retinopathy of prematurity (rop).


Eligibility criteria:
inclusion criteria: * premature new-born infants born at less than 29 weeks of amenorrhea after informed consent has been obtained from a parent or the legal guardian of the infant exclusion criteria: * premature new-born infants presenting a life-threatening condition. persons without national health insurance cover
effect of botulinum toxin injection guided by ultrasound combined with balloon localization on cricopharyngeal achalasia

Conditions: Cricopharyngeal Achalasia; Dysphagia

Summary: cricopharyngeal achalasia refers to incomplete or non-open functional opening of the cricopharyngeal muscle, and after repeated swallowing of food, it still cannot pass through the cricopharyngeal muscle, remaining in the epiglottic valley and the piriform fossa, and even regurgitated into the nasal cavity . neurogenic diseases, myogenic diseases and head and neck tumors are the common causes. patients with chronic underfeeding lead to malnutrition, reduced quality of life, affecting the outcome of the disease. at present, the treatment measures for cricopharyngeal achalasia at home and abroad include balloon dilation technique, surgical incision, botulinum toxin injection. the dilation of the balloon is easy to cause mucosal edema and damage. local infection, massive hemorrhage, local nerve injury and other complications often occur in cricopharyngotomy. botulinum toxin injection relieves muscle spasms and is now widely used to treat dystonia. common injection localization methods include ct, ultrasound, electromyography and endoscopy. ultrasound-guided injection is a new technique of visualization, simple and non-radiation injection guidance, which can observe the injection process and drug injection position in real time. fixation with a balloon can further improve the accuracy of the injection. in this study, botulinum toxin was injected into the cricopharyngeal muscle by ultrasound combined with balloon.

under the ultrasound combined with balloon fixation, two injection sites were selected from the left upper esophageal sphincter, and 30u was injected respectively, and one injection site was selected from the right side, and 30u was injected. in addition, the patient also received routine swallowing training once a day for 30 minutes.

Eligibility criteria:
inclusion criteria: * the videofluoroscopic swallowing study (vfss) confirmed that the cricopharyngeal muscle was not open/closed * patients with no significant improvement in swallowing function after more than 2 weeks of standardized rehabilitation therapy (fois unchanged or decreased) * in the presence of swallowing initiation, vfss is seen in swallowing with an upward motion of the hyoid greater than half the height of the c3 cone * vital signs stable, conscious, treatment cooperative * the patient himself or his family members sign the written informed consent voluntarily exclusion criteria: * patients with severe cognitive impairment, mental illness, and severe cardiopulmonary disease * the structure of the throat is abnormal * malignant tumor patient * infection or wound at the injection site * people allergic to botulinum toxin * bleeding tendency and coagulation disorder

Keywords: botulinum toxins
evaluating the safety and clinical efficacy of elderberry extract in patients with influenza

Conditions: Influenza, Human

Summary: this research is being done to determine if an extract of cooked elderberries will help decrease the duration and severity of influenza symptoms in patients with confirmed influenza. involvement in this study requires an initial patient screening at the time of their emergency department visit in order to confirm eligibility for the study. once patients have been consented and enrolled as a participant, they will be randomized to take by mouth either elderberry extract or a placebo (a similar appearing and tasting liquid without elderberry) for a duration of 5 days. study information regarding medication adherence, body temperature, symptoms, severity of symptoms, and any possible side effects will be collected from daily phone surveys conducted by the study coordinator. participation in the study will end after at least 5 days once the patient has not had a temperature above 100°f and has had no influenza symptoms for at least 24 hours, or after 21 days in the study, whichever occurs first.


Eligibility criteria:
inclusion criteria: * with 48 hours or less of an influenza illness documented by polymerase chain reaction * have at least 2 of the following 7 influenza symptoms (nasal congestion, sore throat, cough, aches and pains, fatigue, headaches, and chills or sweats) graded as either moderate or severe * have access to a phone * subjects are capable of giving informed consent or have an acceptable legally authorized representative capable of giving consent on the subject's behalf with informed assent given by subject. * have been prescribed or offered a prescription for oseltamivir (tamiflu) exclusion criteria: * known allergy to elderberry extract or oseltamivir * use of antibiotic or antiviral medication on presentation to the study * women who are pregnant, breastfeeding women, or do not agree to appropriate contraception (abstinence, hormonal, intrauterine device, and barrier) to prevent pregnancy during the study. * patients with hiv * patients with cystic fibrosis * patients taking elderberry extract

Keywords: elderberry influenza
new acute treatment for stroke - the effect of remote perconditioning

Conditions: Acute Stroke

Summary: this study is a blinded randomized study. randomization for treatment/not treatment with remote perconditioning takes place during transportation to the hospital. this is because the investigators' hypothesis states that remote perconditioning is neuro-protective and the effect is proportionally larger with early treatment. as the size of the effect is unknown, the investigators will use multiple magnetic resonance imaging (mri) scans to determine the size of a potential neuro-protective effect. the aims of this study are: 1. to describe method of remote perconditioning in clinical practice regarding feasibility. pros and cons and potential limitations. 2. to estimate the size of the effect of remote perconditioning in combination with recombinant tissue plasminogen activator (rtpa) treatment within four and a half hours of onset of symptoms.

final inclusion and informed consent takes place after first mri in patients eligible for rtpa. follow-up mri after 24h and 1 month. clinical outcome at 3 months.

Eligibility criteria:
inclusion criteria: * significant ischemic stroke suspicion (nihss 1-24) and paresis of an extremity. * treatment with rtpa within 4.5 hours from debut of symptoms. * age above 18 (changed from 01.01.2010 to no upper age limit) * independent in daily living before the acute onset of symptoms. (mrs\</=2) * mr scan showing dwi lesion, consistent with acute ischemic stroke. exclusion criteria: * contraindications for iv rtpa * onset of symptoms older than 4.5 hours * previous diseases of the brain: intracranial aneurisms or arteriovenous malformations. brain surgery or hemorrhagic stroke. former ischemic stroke within the last 3 months. * heart diseases: infectious endocarditis or suspicion of septic emboli, pericarditis, ventricular thrombosis, aneurisms of the heart wall or major heart failure. * serious diseases: cancer, aids, dementia, significant abuse, renal failure, liver diseases such as liver failure, cirrhosis, portal hypertension, active hepatitis. * pregnancy * major ischemic stroke where the patient is unconscious.(nihss \> 25). * symptoms suspect for migraine, multiple sclerosis, tia or another neurological disease than ischemic stroke. mr scan: * contraindications for mri scans * tumor cerebri, cerebral abscesses * known hypersensitivity to gadovist or any of its ingredients, acute or chronic severe renal impairment (gfr \< 30 ml/min/1.73m2), acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. * caution with using gadovist to patients with severe cardiovascular disease, and only to be used after a risk-benefit assessment. * caution with using gadovist in patients with low threshold for seizures. lab data: * blood glucose \ 22 mmol/l

Keywords: stroke neuroprotection remote preconditioning salvage index (%): difference in infarct growth (pwi-dwi)
clinical significance of circulating tumour cells in resectable lung cancer patients

Conditions: Non Small Cell Lung Cancer; Circulating Tumor Cell

Summary: to determine whether the presence of circulating/disseminated tumour cells (ctcs/dtcs) in the blood and bone marrow of the resectable lung cancer (nsclc) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.


Eligibility criteria:
inclusion criteria: non-small cell lung cancer, non-metastatic exclusion criteria: prior neoadjuvant chemoradiotherapy prior lung cancer cancer duplicity
mirena observational program

Conditions: Contraception; Menorrhagia; Endometrial Hyperplasia; Estrogen Replacement Therapy

Summary: mirena is used for long-term in kazakhstan, and in our observational program we would like to study patients distribution per indications of mirena, and also patient compliance within a year after mirena insertion. for patients with all approved indications for mirena use: contraception, treatment of menorrhagia and protection from endometrial hyperplasia during estrogen replacement therapy


Eligibility criteria:
inclusion criteria: * patients older than 18 years with previously taken decision of their gynecologist to insert mirena according to registered indications exclusion criteria: * all patients with contraindications to mirena insertion, according to approved prescribing information.
the influence of advanced age, obesity and diabetes type on course and outcome of pregnancy with diabetes mellitus.

Conditions: Diabetes Mellitus

Summary: results of this project will enable investigators to get information and to compare maternal and pregnancy characteristics and perinatal outcomes of women with different types of diabetes mellitus and to identify the independent risk factors for adverse perinatal outcomes. particularly, the impact of the advanced age, obesity, and type of diabetes on the course and outcome of pregnancy will be evaluated.

the prevalence of obesity and metabolic diseases (such as type 2 diabetes mellitus, dyslipidaemia, and cardiovascular diseases) has increased in recent years, in both industrialized and developing countries. diabetes mellitus (dm) is one of the most common disorders which occurred during pregnancy. approximately 15% of pregnancies worldwide are thought to be affected by preexisting or gestational insulin-dependent (type 1) or independent (type 2) diabetes mellitus (dm). the utility of mid- and third trimester ultrasound parameters will be assessed for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus. the importance of mid-trimester uterine artery blood flow and foetal biometry will be investigated for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus. moreover, an investigation of the utility of third trimester (measured at 30 and 34 weeks of gestation) ultrasound scan will be carried out for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus. additionally, researchers will assess the relationship between the cerebro-placental ratio (cpr) and intrapartum and perinatal outcomes in pregnancies complicated by different types of diabetes mellitus to determine if the cpr measured at 30 and 34 weeks of gestation is predictive of adverse obstetric and perinatal outcomes. at the end, investigators will evaluate the role of the addition of the uapi to the cpr, alone or as cpur \[cerebro-placental-uterine ratio (cpur)\], in the improvement of the ability of cpr to predict apo at the end of pregnancy in any subgroup of diabetic patients. finally, this project will enable precise intervention and resource saving as well as provide evidence for preventable targets development.

Eligibility criteria:
inclusion criteria: * all pregnant women with diabetes mellitus (18 yo and older). exclusion criteria: * cases of multiple pregnancies * cases of long-term use of corticosteroids * cases complicated by congenital fetal abnormalities or aneuploidy.
the carrier rates of pseudomonas aeruginosa in family members of children with cystic fibrosis

Conditions: Pseudomonas Aeruginosa; Cystic Fibrosis

Summary: pseudomonas aeruginosa (pa) is the bacterium that causes one of the most consequential lung infections in people with cf. many young children do not have pa in their lungs but will become infected as they get older. the investigators want to learn more about how pa is passed from person to person, especially to someone with cystic fibrosis (cf).

people with cf (cystic fibrosis) often have lung infections which occur repeatedly or worsen over time. the lung infections are most often caused by bacteria. pseudomonas aeruginosa (pa) is the bacterium that causes one of the most consequential lung infections in people with cf. many young children do not have pa in their lungs but will become infected as they get older. the investigators want to learn more about how pa is passed from person to person, especially to someone with cf. the respiratory secretions of someone colonized with pa can transmit or pass on the bacterium. the bacterium can be passed through direct contact by two individuals kissing or touching hands. another way to pass pa is by indirect contact such as touching an object like an eating utensil or drinking glass that has been used by someone with pa. there are many unanswered questions about pa lung infections in people with cf. for example, it is not known why some people with cf develop pa lung infections earlier than others. nor is it known why it is difficult to eradicate pa in some children and why some children's condition to deteriorate quicker than other after becoming infected with pa. biological parents of children with cf are carriers of one cf causing gene mutation. it is also possible that they are carriers of additional, but milder, cf-related gene mutations. it is possible that the carrier status of the parents of cf children place them at risk of acquiring and carrying pa in their lungs. biological parents of children who have cf will be asked to participate. this study plans to assess the frequency of pa in biological parents and to correlate the clinical and microbiological status of cf children with pa carrier rates of their parents. parents will be asked to complete questionnaires at one routine, clinic visit, have nasal and throat cultures collected during their child's routine scheduled visit and again 3-4 months later (at another routine visit). the investigators are also asking permission to review the medical records of their child with cf.

Eligibility criteria:
inclusion criteria: * biological parents of children with cf will be invited to participate and included if their children meet the following criteria: * children's age is more than 5 years and less than 20 years of age. exclusion criteria: * biological parents of children younger than 5 years of age or older than 20 years of age. * step parents.

Keywords: pseudomonas aeruginosa cystic fibrosis
apatinib in the treatment of advanced non-squamous non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: apatinib is a new kind of vascular endothelial growth factor receptor(vegfr) tyrosine kinase inhibitors (tkis). the investigators have finished the preclinical and phase i and phase ii clinical study for apatinib and found its satisfactory anti-tumor activity and tolerated toxicities. a disease-control rate of 75% was found in lung cancer patients. in the present phase iii trial, the investigators will further evaluate the efficacy and toxicities of apatinib in the treatment of advanced non-squamous non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: 1. patients 18 to 70 years of age 2. documented pathological evidence of advanced non-squamous non-small cell lung cancer with measurable lesions 3. failure of epidermal-growth-factor receptor (egfr) tkis target treatment and second-line or more regimens of chemotherapy 4. eastern cooperative oncology group (ecog) performance status between 0 and 1 5. patients had to have recovered from any toxic effects of therapy 6. patients with brain/meninges metastasis should keep stable disease for 2 months before randomisation 7. adequate hematologic and biochemical values were required exclusion criteria: 1. presence of small-cell lung cancer alone or with nsclc 2. pregnant or breast-feeding women 3. severe or uncontrolled systemic disease such as clinically significant hypertension(systolic pressure \> 140 mmhg，diastolic pressure \> 90 mmhg), cardiac ischemia and infarction, ventricular arrhythmias(qt ≥ 440ms) and grade 1 cardiac insufficiency 4. difficulties in taking pills (inability to swallow tablets,gi tract resection, chronic bacillary diarrhea and intestinal obstruction) 5. coagulation disfunction,hemorrhagic tendency or receiving anticoagulant therapy 6. ≥ ctcae 2 pneumorrhagia or ≥ ctcae 3 hemorrhage in other organs within 4 weeks 7. bone fracture or wounds that was not cured for a long time 8. arterial thrombus or phlebothrombosis within 6 months and taking anticoagulant agents 9. mental diseases and psychotropic substances abuse 10. previous treatment with an experimental agent within 4 weeks 11. previous treatment with vegfr、platelet derived growth factor receptor(pdgfr) tkis 12. other coexisting malignant disease (apart from basal-cell carcinoma and carcinoma in situ of uterine cervix)

Keywords: apatinib non-small cell lung cancer vegfr tkis
electromyographic control of the response in the application of vojta therapy in people with brain injury.

Conditions: Abdominal Muscles

Summary: a non-randomized clinical trial on a cohort of healthy subjects of legal age, both sexes, recruited from the university community and who will be randomly distributed into two groups (experimental and control). the objective will be to determine the feasibility of the standardized intervention protocol on the stabilizing muscles of the trunk (external oblique and internal oblique) before, during and after the application of vojta therapy, and to know the effects produced on the musculature studied after performing the intervention.


Eligibility criteria:
brain injury group inclusion criteria : * over 18 and under 80 years of age * persons with a medical diagnosis of brain damage secondary to stroke * have preserved the ability to walk, even with some type of orthopedic some type of orthopedic aid, exclusion criteria: * over 80 years * healthy people group without brain damage inclusion criteria : * over 18 and under 80 years of age * healthy people * full cognitive capacity. exclusion criteria: * subjects with neuro-muscular pathologies that affect the abdominal muscles, previous surgeries in the area or any chronic neurological or organic disorder that may alter the results. * fever
impact of job related activities on female physiotherapist and dentist during internship year

Conditions: Job Related Stress

Summary: response of hand grip, pinch grip and body composition to type of effort between female physiotherapist and female dentist at internship year.

fifty physiotherapist and fifty dentist females will be selected from faculty of physical therapy and faculty of dentistry at badr university in cairo buc, both at internship year, and will be assigned into two groups. group a consists of fifty physiotherapist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work. group b consists of fifty dentist females will participate in this group and will be assessed at the beginning of the study and after 6 months of clinical work. digital hand dynamometer will be used to assess hand grip strength and inbody device will be used to assess changes in body composition at the beginning and the end of the study.

Eligibility criteria:
inclusion criteria: 1. fifty physiotherapist females and fifty dentist females at internship year. 2. their age will be ranged from 21 to 24 years old. 3. they are medically stable and consented to participate in the study. 4. they are able to follow instructions. exclusion criteria: 1. history of any pathological disease-causing disorder in metabolism such as thyroid gland disorder. 2. history of muscular or neurological disorder. 3. using any hormonal treatment. 4. following any diet modification method. 5. severe emotional stress.

Keywords: hand grip pinch grip body composition job related activities physiotherapist dentist